
OCEA
Healthcare · Biotechnology · $23,236 market cap
$0.00010.00 (0.0%)Nov 13, 9:30 AM EST
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2023
EPS trend, 90 days to now · +100.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 1 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Apr 8, 2025 | Time not confirmed | -0.24 | 0.01 | +104.2% |
| Feb 26, 2025 | Time not confirmed | — | 0.01 | — |
| Nov 27, 2024 | Time not confirmed | — | -0.20 | — |
| Aug 28, 2024 | Time not confirmed | — | -0.63 | — |
| Apr 15, 2024 | After the close | -0.15 | -0.52 | -246.7% |
| Feb 28, 2024 | Time not confirmed | — | -0.49 | — |
| Nov 29, 2023 | Time not confirmed | -0.15 | -0.53 | -253.3% |
| Aug 14, 2023 | After the close | -0.19 | -0.41 | -115.8% |
| May 24, 2023 | After the close | -0.17 | -0.27 | -58.8% |
| Feb 23, 2023 | Before the open | -0.16 | 0.03 | +119.4% |
| Oct 17, 2022 | Time not confirmed | — | -0.08 | — |
| Jul 11, 2022 | Time not confirmed | — | -0.01 | — |
| Apr 25, 2022 | Time not confirmed | — | -0.01 | — |
Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases in the United States. The company's oncology product candidates include OCX-253 anti-Chi3l1 Single-target mAb and OCX-410 anti-Chi3l1/PD-1 Bi-specific antibody for the treatment of non-small cell lung cancer; and OCX-909 anti-Chi3l1/CTLA-4 Bi-specific…
| Jan 31, 2022 | Time not confirmed | — | -0.04 | — |
| Oct 18, 2021 | Time not confirmed | — | 0.00 | — |